These new low-powered AI chips, developed using Nuvia's designs, are anticipated to help Microsoft and other PC manufacturers compete more effectively with Apple's laptops.

The ongoing trial stems from a licensing agreement dispute related to Qualcomm's $1.4 billion acquisition of Nuvia, a chip startup that was previously licensed to use Arm's architecture.

Negotiations between Arm and Qualcomm lasted for eight months but ultimately failed, resulting in the termination of the Nuvia license and the subsequent lawsuit.

Arm's licensing model is crucial to its business, as it licenses CPU and GPU cores to numerous clients worldwide, making any deviation from royalty agreements potentially damaging to its revenue.

A ruling in favor of Arm could compel Qualcomm to abandon its use of Nuvia technology, possibly forcing it to switch to standard Arm cores or alternative architectures like RISC-V, which would require significant time to implement.

The trial's outcome may disrupt the release of AI computers, as Arm claims Qualcomm's Nuvia-based designs were used to create new AI PC chips, potentially halting shipments of affected laptops, including those from Microsoft.

Arm is seeking the destruction of all Nuvia designs created before the merger with Qualcomm, without requesting monetary damages, while Qualcomm reportedly pays Arm approximately $300 million annually in fees.

Experts suggest that the trial could have far-reaching implications for intellectual property licensing practices, mergers and acquisitions, and contract law within the tech industry.

Despite the legal battle, Qualcomm continues to develop a new generation of processors that incorporate Nuvia technology, which is expected to enhance its competitive edge in the market.

Key witnesses expected to testify include Arm CEO Rene Haas, Qualcomm CEO Cristiano Amon, and Nuvia founder Gerard Williams, highlighting the high stakes involved.

Qualcomm countersued, asserting that its existing licensing agreement with Arm is sufficient and that the lawsuit is detrimental to its business and innovation.

The trial is limited to 22 hours, with jurors expected to deliberate on their verdict soon after the hearings resume, possibly by December 19, 2024.